Teva announces approval of a generic version of forteo® (teriparatide injection), in the u.s.

Parsippany, n.j. & tel aviv, israel--(business wire)--teva pharmaceuticals inc., a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), announced today the approval of a generic version of forteo®1, in the united states. market availability of the product in the u.s. is expected in the coming weeks. teriparatide injection is indicated to treat osteoporosis among certain women and men. please see the below “what is?” section for more information. “we are thrilled to recei.
TEVA Ratings Summary
TEVA Quant Ranking